Introduction

In a closely watched lithium-ion battery patent dispute, a federal jury in the Eastern District of Texas delivered a significant win for Ningde Amperex Technology Limited (ATL) against Chinese rival Zhuhai CosMX Battery Co., Ltd. The February 9, 2024 verdict found CosMX willfully infringed ATL’s battery technology patents — a finding that ultimately triggered court-enhanced damages bringing the total award to approximately $4.7 million.

Case No. 2:22-cv-00232, filed June 24, 2022 and closed April 26, 2024, centered on lithium-ion battery products and three U.S. patents covering advanced battery cell architecture. The case is significant not only for its outcome but for its mixed validity rulings — two asserted patent claims were invalidated, yet the surviving claims sustained both infringement and willfulness findings. For patent attorneys litigating battery technology patents, IP professionals tracking Chinese battery sector disputes, and R&D teams navigating freedom-to-operate risks, this case offers actionable strategic intelligence.

Case Overview

The Parties

The Patents at Issue

Four U.S. patents were asserted, all directed to lithium-ion battery technology, covering structural and compositional innovations in battery cell design:

• • U.S. Patent No. 10,964,987 (‘987 Patent) — Claims 1 and 17 asserted
• • U.S. Patent No. 10,833,363 (‘363 Patent) — Claim 1 asserted
• • U.S. Patent No. 11,329,352 (‘352 Patent) — Claim 1 asserted
• • U.S. Patent No. 10,971,706 (‘706 Patent) — Referenced in proceedings

The Accused Products

CosMX’s commercial lithium-ion battery products were alleged to embody the claimed battery cell structures. Given both companies’ positions in the global battery supply chain, the commercial stakes extended well beyond the damages award itself.

Legal Representation

ATL retained a formidable legal team led by Quinn Emanuel Urquhart & Sullivan LLP alongside Alston & Bird LLP and The Dacus Firm PC. CosMX was represented by Finnegan, Henderson, Farabow, Garrett & Dunner LLP, Norton Rose Fulbright US LLP, Mayer Brown LLP, and Findlay Craft PC.

Litigation Timeline & Procedural History

ATL filed suit on June 24, 2022 in the U.S. District Court for the Eastern District of Texas, a jurisdiction historically favored by patent plaintiffs for its efficient dockets and experienced patent bench. The case was assigned to Chief Judge Rodney Gilstrap, one of the most experienced patent trial judges in the country, having presided over more patent cases than virtually any other federal judge.

The case progressed through approximately 672 days from filing to final judgment — a timeline consistent with complex multi-patent litigation in the Eastern District. Jury trial commenced on February 1, 2024, with the jury returning its unanimous verdict eight days later on February 9, 2024.

Following the verdict, parties filed a Joint Notice on Equitable Issues on April 11, 2024, stipulating that CosMX’s California Unfair Competition Law (UCL) counterclaim was moot, and that affirmative defenses of unclean hands and patent misuse were withdrawn. This streamlined post-verdict proceedings, enabling Final Judgment entry on April 26, 2024 without a separate bench trial on equitable issues.

The Verdict & Legal Analysis

Outcome

The jury returned a unanimous verdict finding:

• • Infringement confirmed on claims 1 and 17 of the ‘987 Patent and claim 1 of the ‘363 Patent and ‘352 Patent
• • Willful infringement established on the asserted claims
• • Compensatory damages of $3,701,108.00 awarded to ATL
• • Claim 1 of the ‘363 Patent — invalidated
• • Claim 1 of the ‘352 Patent — invalidated
• • Claims 1 and 17 of the ‘987 Patent — upheld as valid

Following the verdict, Judge Gilstrap exercised discretion under 35 U.S.C. § 284, enhancing damages by an additional $1,000,000, citing the totality of circumstances and the willfulness finding. The court further awarded pre-judgment interest at the 5-year U.S. Treasury Bill rate, compounded quarterly, and post-judgment interest at the statutory rate under 28 U.S.C. § 1961.

Total recovery for ATL: approximately $4,701,108 plus pre- and post-judgment interest and costs.

Validity Challenge Analysis

The mixed validity outcome is strategically instructive. CosMX successfully invalidated claim 1 of both the ‘363 and ‘352 Patents — a partial defensive win that nonetheless proved insufficient to avoid liability. The survival of claims 1 and 17 of the ‘987 Patent demonstrates the importance of claim diversification in patent prosecution: maintaining multiple independent claims across a patent family creates redundancy that frustrates validity-based invalidity defenses at trial.

Willfulness Finding

The willfulness determination carries particular significance. CosMX’s defense included the aggressive counter-theory that ATL’s June 21, 2021 letter threatening Chinese patent litigation constituted an anticompetitive act — specifically, that it was both objectively baseless and an improper attempt to interfere with competitor business relationships in violation of the Sherman Act and California’s UCL. The jury rejected this defense entirely, finding ATL’s litigation threats were not objectively baseless and that ATL had not engaged in anticompetitive conduct.

This outcome reinforces the high evidentiary bar defendants face when characterizing patent enforcement letters as antitrust violations — particularly where the patent holder ultimately prevails on infringement.

Strategic Takeaways

For Patent Holders:

• Prosecute broad patent families with multiple independent claims across continuation applications to ensure claim survival even when some claims face successful validity challenges
• Pre-litigation enforcement letters, when based on legitimate patent positions, are defensible under antitrust scrutiny — but must be carefully worded
• Willfulness findings remain achievable in Chinese-competitor battery cases where pre-suit notice exists

For Accused Infringers:

• Invalidity remains the most reliable defense path; partial invalidity wins, however, may not prevent substantial damages exposure
• Sherman Act and UCL-based counterclaims face a demanding standard — objective baselessness is difficult to prove against a patentee who ultimately prevails
• Design-around analysis should be initiated immediately upon receipt of any patent enforcement correspondence

For R&D Teams:

• Battery cell architecture patents — including electrode configuration and structural claims — are being actively enforced across Chinese battery sector competitors in U.S. courts
• Freedom-to-operate (FTO) analysis of ATL/CATL patent portfolios is essential for any company developing or importing lithium-ion battery products into the U.S. market

Industry & Competitive Implications

This verdict arrives amid escalating IP competition between major Chinese battery manufacturers as they compete for global market share. ATL v. CosMX reflects a broader pattern: established battery technology leaders increasingly turning to U.S. federal courts to protect innovations against domestic and international competitors.

For the global lithium-ion battery sector — which supplies electric vehicles, consumer electronics, and energy storage systems — this case signals that U.S. patent enforcement is a credible strategic tool even when both parties are Chinese entities. The Eastern District of Texas remains a preferred venue for such disputes.

The $4.7 million award, while modest relative to the scale of commercial battery markets, establishes a damages baseline and creates meaningful litigation risk for competitors. Enhanced damages for willfulness underscore that CosMX’s conduct was viewed as beyond ordinary infringement — a reputational and financial consideration for any company managing patent risk in this sector.

Companies holding battery technology patents should view this case as validation of the enforcement value of well-prosecuted continuation patent families. Companies competing in battery supply chains should prioritize comprehensive patent clearance programs, particularly for structural battery cell innovations covered by ATL’s and CATL’s extensive U.S. patent portfolios.